Annie Chicoye
Annie Chicoye is Senior Principal at IMS Health in France. She has a strong background in Health Economics, health technology assessment and public health and industrial policies.
Claude Le Pen, PhD
Professor of Economics at Paris-Dauphine University and member of the Strategic Committee of IMS France. He has experience of being member of various committees, including the French Transparency Commission.
David S. Battleman, MD, MSc, MBA
Dr. Battleman has over 15 years experience in the life sciences and has worked in a variety of settings, including healthcare consulting, the pharmaceutical industry, as well as in academia.
Elisabeth Hazard, PhD
Founder of ValueMedics Research with over 15 years in the health care industry, Dr. Hazard is a pioneer in the area of value communications.
Frank-Ulrich Fricke, PhD
Principal, Health Economics and Outcomes Research at IMS in Germany, with a particular focus on health economic evaluations (cost analysis, economic modeling, cost effectiveness analysis), market access strategies and health policy.
Jonothan C. Tierce, CPhil
Founder of ValueMedics Research with over 20 years of experience in health economics research and consulting for the pharmaceutical, medical device and diagnostics industries.
Joshua S. Benner, PharmD, ScD
An expert in the area of patient compliance, Dr Benner's capabilities include the design and analysis of prospective trials, retrospective studies in administrative and medical records databases, primary data collection through patient surveys or chart abstractions, and economic modeling.
Karin Berger
Principal, Health Economics and Outcomes Research at IMS in Germany, with extensive experience in health outcomes research, health economic evaluation and modelling studies
Laurence Fong
Principal, Pricing and Market Access at IMS Australia with extensive experience in leading and managing economic and public affairs in the pharmaceutical and health industry.
David Grant, MBA
Senior Principal, Health Economics and Outcomes Research at IMS in the UK, specialises in providing strategic advice, particularly for products in early development and has led client projects relating to burden-of-illness reviews, reimbursement and market access environmental analysis.
Pippa Anderson, MSc
Senior Principal, Health Economics and Outcomes Research at IMS in London, with experience is in qualitative research relating to health care and health economics, measurement and valuation of health, and in the communication of value evidence to health care decision makers through the medium of the Value Dossier - the crucial end product of outcomes research programmes.
Adam Lloyd, MPhil
Senior Principal, Health Economics and Outcomes Research at IMS in London, specialist in economic analysis and economic modelling with extensive experience of leading economic evaluations of products in clinical development and post-launch, decision-analytic and Markov modelling and in using health economics in reimbursement and marketing activities in continental Europe.
Michael Minshall, MPH
Principal, Health Economics and Outcomes Research, at IMS in the US, with particular expertise in cost-utility analysis, utility assessments, health-related quality of life (HRQoL) analysis, and prospective economic evaluations within Phase III clinical trials.
Olaf Pirk, MD, PhD
Principal, Health Economics and Outcomes Research at IMS in Germany, with a particular focus on economics evaluations, market access strategics and health policy.
Xavier Badia, MD, MPH, PhD
Principal, HEOR of Health Outcomes Research Europe, a unit of IMS, in Spain, with extensive public sector research experience in outcomes research, patient reported outcomes (PROs), effectiveness and cost-effectiveness evaluations.